An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

292

Participants

Timeline

Start Date

December 19, 2017

Primary Completion Date

January 13, 2021

Study Completion Date

January 10, 2025

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

nivolumab

Specified dose on specified days

DRUG

docetaxel

Specified dose on specified days

DRUG

enzalutamide

Specified dose on specified days

DRUG

rucaparib

Specified dose on specified days

DRUG

prednisone

Specified dose on specified days

Trial Locations (66)

0

Local Institution - 0050, Clayton

Local Institution - 0027, Montería

Local Institution - 0026, Medellín

1199

Local Institution - 0043, CABA

1426

Local Institution - 0052, CABA

Local Institution - 0042, Capital Federal

2050

Local Institution - 0015, Camperdown

2145

Local Institution - 0017, Westmead

3084

Local Institution - 0013, Heidelberg

4101

Local Institution - 0014, South Brisbane

5003

Local Institution - 0062, Villa Siburu

5112

Local Institution - 0016, Elizabeth Vale

10032

Local Institution - 0068, New York

12208

Local Institution - 0038, Albany

13273

Local Institution - 0030, Marseille

18103

Local Institution - 0053, Allentown

20850

Local Institution - 0040, Rockville

22031

Local Institution - 0039, Fairfax

25030

Local Institution - 0033, Besançon

27710

Local Institution - 0041, Durham

28041

Local Institution - 0045, Madrid

30060

Local Institution - 0009, Marietta

31008

Local Institution - 0046, Pamplona

33176

Local Institution - 0037, Miami

36526

Local Institution - 0036, Daphne

37000

Local Institution - 0054, León

37075

Local Institution - 0006, Göttingen

39202

Local Institution - 0069, Jackson

40207

Local Institution - 0065, Louisville

41013

Local Institution - 0047, Seville

44130

Local Institution - 0061, Guadalajara

44280

Local Institution - 0048, Guadalajara

45122

Local Institution - 0001, Essen

48201

Local Institution - 0012, Detroit

56068

Local Institution - 0007, Koblenz

63000

Local Institution - 0032, Clermont-Ferrand

63110

Local Institution - 0011, St Louis

68130

Local Institution - 0035, Omaha

69008

Local Institution - 0031, Lyon

70112

Tulane University, New Orleans

80230

Local Institution - 0025, Culiacán

81675

Local Institution - 0064, München

92270

Local Institution - 0010, Rancho Mirage

94800

Local Institution - 0029, Villejuif

97225

Local Institution - 0024, Portland

2540364

Local Institution - 0051, Viña del Mar

8420383

Local Institution - 0034, Santiago

90035001

Local Institution - 0021, Porto Alegre

06520

Local Institution - 0049, New Haven

02118

Boston Medical Center, Boston

C1280

Local Institution - 0044, Buenos Aires

30110-022

Local Institution - 0020, Belo Horizonte

30130-090

Local Institution - 0074, Belo Horizonte

81480-580

Local Institution - 0075, Curitiba

98700-000

Local Institution - 0018, Ijuí

13075-460

Local Institution - 0022, Campinas

05652-900

Local Institution - 0071, São Paulo

22793-080

Local Institution - 0019, Rio de Janeiro

01308-050

Local Institution - 0073, São Paulo

V1Y 5L3

Local Institution - 0067, Kelowna

E1C 6Z8

Local Institution - 0059, Moncton

L8V 5C2

Local Institution - 0055, Hamilton

H2X 0C1

Local Institution - 0066, Montreal

G1J 1Z4

Local Institution - 0056, Québec

D-69120

Local Institution - 0004, Heidelberg

07747

Local Institution - 0002, Jena

All Listed Sponsors
collaborator

Clovis Oncology, Inc.

INDUSTRY

collaborator

Astellas Pharma Inc

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY

NCT03338790 - An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer | Biotech Hunter | Biotech Hunter